We don’t mean Zimmer Biomet Holdings, Inc. is moving to Ireland. The orthopedic giant is simply lowering its carbon footprint.
Zimmer Biomet Goes Green
1 min read Premium comments
Secondary
The company announced on September 7, 2016, that it’s Warsaw, Indiana-based headquarters is going to be wholly powered by renewable, green energy, in compliance with the U.S. Environmental Protection Agency’s (EPA) Green Power Partnership program.
Green power, according to the company, is zero-emissions electricity that is generated from environmentally preferable renewable resources, such as wind, solar, geothermal, biogas, eligible biomass, and low-impact hydro. The company’s headquarters building will receive green power from Northern Indiana Public Service Company (NIPSCO), an approved provider of green power for the EPA’s Green Power Program, which allows homes and businesses to designate a portion, or all, of their monthly electric usage to be attributable to electricity generated by renewable energy sources.
The Green Power Partnership is a voluntary program that encourages organizations to use green power as a way to reduce the environmental impacts associated with electricity use. The Partnership currently has more than 1, 400 Partner organizations voluntarily using billions of kilowatt-hours of green power annually.
Robin Barney, the Zimmer Biomet’s senior vice president for global operations and logistics, said the green power conversion will cover 100% of the headquarters. “Sustainably and responsibly sourcing our electric power is a critical milestone in advancing Zimmer Biomet’s longstanding commitment to sustainability, and we hope our efforts inspire local area businesses and residents to join the EPA’s Green Power Program to collectively reduce our region’s environmental footprint.”
The company’s Warsaw production facilities employ approximately 2, 800 employees. The announcement did not state if the production facility was included in the program.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.